ADME INVESTIGATION

R&D Pipeline

ReadyCell supports the pharmacological evaluation of drug candidates to minimize costs, facilitates lead optimization, and speeds up new drug development.

Developing innovative in vitro tools for preclinical stages, main efflux and uptake transporters, and toxicity-metabolism.

ReadyCell is fully committed to innovation. We are continuously expanding our product portfolio based on the latest drug transporter science results, the pharmaceutical industry’s needs, and suggestions of the various regulatory agencies. Our mission is to continue to develop reliable, high quality and practical tools that optimize the whole drug discovery process.

Projects Graph

Proof of Concept

  • Ready-to-use Hepatocytes
  • Ready-to-use Cardiomyocytes

Late Development

  • PreadyTake MATE2-K
  • PreadyTake OAT1
  • PreadyTake OAT3

Validation

  • PreadyPort OAT1/BCRP
  • PreadyTake OATP1B1
  • PreadyTake OATP1B3

Market Access

  • Preadyctive MRP2

 

Are you interested in developing innovative in vitro systems?

ReadyCell Scientists are available to discuss tailored projects indicated for drug discovery and biomedical research.

Partners

NCI

Collaborations

ReadyCell is involved in several research projects with public and private organizations and is always keen to examine new scientific collaborations.

CIEN 2019 – SEGURAM

  • SEGURAM is a consortium of seven companies whose main objective is to research and develop new sustainable strategies along the meat industry’s entire value chain to increase productivity and food security while reducing the use of antibiotics.
  • ReadyCell is developing new in vitro gut-on-a-chip models to evaluate the efficacy of active ingredients and bioavailability of nutrients.

 

MISIONES 2020 – BIOPRINTIA

  • BioPrintIA is developing innovative biotechnology of tailor-designed bioimplants based on artificial intelligence and 3D bio-printing. The medical device will be indicated for osteoarticular tissue transplants, significantly reducing degenerative knee symptomatology and considerably improving the patient’s quality of life.

  • ReadyCell’s expertise will help to develop a cell-based in vitro system, which artificially reproduces physiological osteoarticular conditions.

HORIZON 2020 – FETOPEN

  • StretchBio aims to boost and transform biomedical research and clinical diagnosis through the development of a novel compact device for in vitro continuous two-dimensional mechanical stress monitoring of living tissues for drug screening purposes in personalized cancer medicine.
  • ReadyCell will command the commercialization possibilities of the StretchBio project thanks to its leading position and experience in the biomedical field and its network of distribution partners worldwide.

Externalizing your Cell Culture

A new study uses CacoGoblet in a gut-liver-organ-on-a-chip

A new study uses CacoGoblet in a gut-liver-organ-on-a-chip

An investigation led by the researcher Nicoló Milani was published in the prestigious analytical journal Lab on a Chip. The CacoGoblet kit was employed to investigate the permeability and the metabolism of the compound in a gut-liver-organ-on-a-chip (OoC).

Caco-2 Permeability Assay Protocol

Caco-2 Permeability Assay Protocol

Caco-2 cells assay is a reference assayto evaluate intestinal permeability in drug discovery stages, optimizing novel compounds screening.

ReadyCell is attending the 4th Brain Barriers Summit in Boston

ReadyCell is attending the 4th Brain Barriers Summit in Boston

Our ReadyCell sales representative Carla Sapienza will travel next August 29th, 30th and 31st to Boston to attend the Brain Barriers Summit, an event that aims to join industry experts through a discursive forum and evaluate how neuropharmaceuticals can be targeted.

New hyperoxia drug study references CacoReady Kits

New hyperoxia drug study references CacoReady Kits

The publication, entitled Daily Intraperitoneal Administration of RGZ Does Not Improve Lung Function or Alveolarization in Preterm Rabbits Exposed to Hyperoxia, was aimed at testing the efficacy of three types of Thiazolidenoides (TZN) in preterm rabbits with bronchopulmonary dysplasia.